WallStreetZenWallStreetZen

NASDAQ: LFCR
Lifecore Biomedical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their LFCR stock forecasts and price targets.

Forecast return on equity

Is LFCR forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is LFCR forecast to generate an efficient return on assets?

Company
-2.44%
Industry
156.72%
LFCR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LFCR earnings per share forecast

What is LFCR's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.81
Avg 2 year Forecast
-$0.64
Avg 3 year Forecast
-$0.15

LFCR revenue forecast

What is LFCR's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$132.5M
Avg 2 year Forecast
$147.7M
Avg 3 year Forecast
$182.9M

LFCR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
LFCR$7.79N/AN/A
ACB$5.40N/AN/A
OGI$1.92N/AN/A
TKNO$4.71N/AN/A
DERM$7.67$12.67+65.15%Strong Buy
View Top Pharmaceutical Stocks

Lifecore Biomedical Stock Forecast FAQ

What is LFCR's earnings growth forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 364.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.

Lifecore Biomedical's earnings in 2025 is N/A.On average, 7 Wall Street analysts forecast LFCR's earnings for 2026 to be -$30,287,799, with the lowest LFCR earnings forecast at -$34,881,174, and the highest LFCR earnings forecast at -$23,997,198. On average, 7 Wall Street analysts forecast LFCR's earnings for 2027 to be -$23,982,212, with the lowest LFCR earnings forecast at -$31,209,471, and the highest LFCR earnings forecast at -$16,916,058.

In 2028, LFCR is forecast to generate -$5,732,352 in earnings, with the lowest earnings forecast at -$5,507,554 and the highest earnings forecast at -$5,900,950.

If you're new to stock investing, here's how to buy Lifecore Biomedical stock.

What is LFCR's revenue growth forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.

Lifecore Biomedical's revenue in 2025 is N/A.On average, 7 Wall Street analysts forecast LFCR's revenue for 2026 to be $4,963,167,649, with the lowest LFCR revenue forecast at $4,743,989,490, and the highest LFCR revenue forecast at $5,122,024,982. On average, 7 Wall Street analysts forecast LFCR's revenue for 2027 to be $5,534,529,517, with the lowest LFCR revenue forecast at $5,206,324,274, and the highest LFCR revenue forecast at $5,756,704,985.

In 2028, LFCR is forecast to generate $6,853,719,771 in revenue, with the lowest revenue forecast at $6,546,495,685 and the highest revenue forecast at $7,096,501,732.

What is LFCR's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: LFCR) forecast ROA is -2.44%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 156.72%.

What is LFCR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that LFCR's EPS will be -$0.81 for 2026, with the lowest EPS forecast at -$0.93, and the highest EPS forecast at -$0.64. On average, analysts forecast that LFCR's EPS will be -$0.64 for 2027, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.45. In 2028, LFCR's EPS is forecast to hit -$0.15 (min: -$0.15, max: -$0.16).

What is LFCR's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: LFCR) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.